MX2018006973A - Anticuerpos anti-cd73 humanizados. - Google Patents

Anticuerpos anti-cd73 humanizados.

Info

Publication number
MX2018006973A
MX2018006973A MX2018006973A MX2018006973A MX2018006973A MX 2018006973 A MX2018006973 A MX 2018006973A MX 2018006973 A MX2018006973 A MX 2018006973A MX 2018006973 A MX2018006973 A MX 2018006973A MX 2018006973 A MX2018006973 A MX 2018006973A
Authority
MX
Mexico
Prior art keywords
antibodies
humanized
humanized anti
cancer
binding
Prior art date
Application number
MX2018006973A
Other languages
English (en)
Inventor
Wen Chang Hwai
Johann Frey Gerhard
A Miller Richard
Piccione GRIFFIN Emily
Original Assignee
Corvus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvus Pharmaceuticals Inc filed Critical Corvus Pharmaceuticals Inc
Publication of MX2018006973A publication Critical patent/MX2018006973A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Abstract

Se proporcionan en el presente documento, entre otros, anticuerpos 1E9 humanizados capaces de unirse al CD73. Los anticuerpos humanizados son útiles para el tratamiento del cáncer. Adicionalmente se proporcionan en el presente documento ácidos nucleicos que codifican anticuerpos 1E9 humanizados y métodos de inhibición de la proliferación utilizando los anticuerpos humanizados proporcionados en el presente documento.
MX2018006973A 2015-12-09 2016-12-09 Anticuerpos anti-cd73 humanizados. MX2018006973A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562265357P 2015-12-09 2015-12-09
US201662289694P 2016-02-01 2016-02-01
US201662346327P 2016-06-06 2016-06-06
PCT/US2016/065968 WO2017100670A1 (en) 2015-12-09 2016-12-09 Humanized anti-cd73 antibodies

Publications (1)

Publication Number Publication Date
MX2018006973A true MX2018006973A (es) 2019-05-16

Family

ID=59013359

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006973A MX2018006973A (es) 2015-12-09 2016-12-09 Anticuerpos anti-cd73 humanizados.

Country Status (13)

Country Link
US (2) US10822426B2 (es)
EP (1) EP3387442A4 (es)
JP (2) JP7391510B2 (es)
KR (1) KR20180134837A (es)
CN (2) CN114805575A (es)
AU (1) AU2016366548B2 (es)
CA (1) CA3007646A1 (es)
CL (1) CL2018001512A1 (es)
EA (1) EA201891366A1 (es)
IL (1) IL259927B2 (es)
MX (1) MX2018006973A (es)
WO (1) WO2017100670A1 (es)
ZA (1) ZA201803874B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3387442A4 (en) * 2015-12-09 2019-05-08 Corvus Pharmaceuticals, Inc. HUMANIZED ANTI-CD73 ANTIBODIES
WO2018013611A1 (en) * 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
CN109476755B (zh) 2017-01-24 2020-12-04 天境生物科技(上海)有限公司 Cd73抗体及其用途
CN110382544B (zh) 2017-03-16 2023-12-22 先天制药公司 用于治疗癌症的组合物和方法
EP3606962A4 (en) * 2017-04-04 2020-12-23 Corvus Pharmaceuticals, Inc. TREATMENT METHODS FOR HIGH CD73 TUMORS
SG11202002192QA (en) 2017-10-06 2020-04-29 Innate Pharma Restoration of t cell activity via the cd39/cd73 axis
PE20211001A1 (es) 2018-02-27 2021-06-01 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
CN110240654A (zh) * 2018-03-07 2019-09-17 复旦大学 结合cd73的抗体-药物偶联物
CN111867628A (zh) * 2018-03-09 2020-10-30 东莞凡恩世生物医药有限公司 抗cd73抗体及其用途
CR20200392A (es) * 2018-03-09 2020-11-17 Agenus Inc Anticuerpos anti-cd73 y métodos de uso de los mismos
WO2019191133A1 (en) 2018-03-27 2019-10-03 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
EA202092518A1 (ru) 2018-06-18 2021-08-23 Иннейт Фарма Композиции и способы лечения рака
KR20210100099A (ko) * 2018-11-05 2021-08-13 코버스 파마슈티칼스, 인크. B 세포 활성화 cd73 항체
KR20210093255A (ko) * 2018-11-12 2021-07-27 지앙수 헨그루이 메디슨 컴퍼니 리미티드 항-cd73 항체, 이의 항원 결합 단편 및 이의 적용
CN111499747B (zh) * 2019-01-11 2022-03-18 康诺亚生物医药科技（成都）有限公司 一种抗cd73单克隆抗体及其应用
CN111434688A (zh) * 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
KR20220012292A (ko) 2019-05-23 2022-02-03 브리스톨-마이어스 스큅 컴퍼니 세포 배양 배지를 모니터링하는 방법
WO2020244606A1 (zh) * 2019-06-06 2020-12-10 北京加科思新药研发有限公司 对cd73具有特异性的结合分子及其用途
CN112300279A (zh) * 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
CN113454121B (zh) * 2019-08-21 2022-03-08 和铂医药(上海)有限责任公司 抗cd73抗体及其应用
EP4025605A1 (en) 2019-09-06 2022-07-13 Symphogen A/S Anti-cd73 antibodies
MX2022005086A (es) * 2019-11-01 2022-08-11 Corvus Pharmaceuticals Inc Anticuerpos anti-cd73 inmunomoduladores y usos de estos.
US20210230294A1 (en) 2020-01-03 2021-07-29 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
WO2021213466A1 (zh) * 2020-04-22 2021-10-28 中山康方生物医药有限公司 抗cd73的抗体及其用途
WO2021241729A1 (ja) * 2020-05-29 2021-12-02 ブライトパス・バイオ株式会社 抗ｃｄ７３抗体およびその用途
JP2023532234A (ja) 2020-06-22 2023-07-27 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ｃｄ７３抗体とその用途
CN116406369A (zh) 2020-10-05 2023-07-07 百时美施贵宝公司 用于浓缩蛋白质的方法
TW202222840A (zh) * 2020-12-11 2022-06-16 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ７３的抗原結合蛋白及其應用
CA3207066A1 (en) 2020-12-29 2022-07-07 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
EP4299589A1 (en) * 2021-02-24 2024-01-03 Novoprotein Scientififc Inc. Anti-human cd73 antibody and use thereof
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN115991772B (zh) * 2022-08-12 2023-09-01 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN116813786A (zh) * 2023-08-03 2023-09-29 贝达药业股份有限公司 抗cd73抗体及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US7456260B2 (en) * 2002-06-17 2008-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized antibody
US20070134249A1 (en) * 2005-12-08 2007-06-14 Genitope Corporation Combination therapy and antibody panels
DK2170959T3 (da) * 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
JP2012504961A (ja) * 2008-10-06 2012-03-01 ミネルバ バイオテクノロジーズ コーポレーション Ｍｕｃ１＊抗体
US8362210B2 (en) * 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2012022682A1 (en) 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Anti-human igg1 antibody
WO2013006449A2 (en) 2011-07-01 2013-01-10 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
TWI595007B (zh) * 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
WO2014130965A1 (en) 2013-02-22 2014-08-28 Amgen Inc. Gastrokine-1 (gkn1) binding proteins and methods of treatment
WO2014153424A1 (en) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
CN106414494B (zh) 2013-11-12 2020-09-18 Ogd2药物 具有促凋亡活性的人IgG1衍生的抗体
EP3134111B1 (en) * 2014-04-25 2022-06-08 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
EP3259288A1 (en) * 2015-02-20 2017-12-27 Innate Pharma Cd73 blockade
EP3387442A4 (en) * 2015-12-09 2019-05-08 Corvus Pharmaceuticals, Inc. HUMANIZED ANTI-CD73 ANTIBODIES

Also Published As

Publication number Publication date
CN114805575A (zh) 2022-07-29
CN109154611B (zh) 2022-04-08
JP7391510B2 (ja) 2023-12-05
US20190077873A1 (en) 2019-03-14
JP2019503709A (ja) 2019-02-14
CN109154611A (zh) 2019-01-04
EP3387442A4 (en) 2019-05-08
CL2018001512A1 (es) 2019-03-08
KR20180134837A (ko) 2018-12-19
AU2016366548A1 (en) 2018-06-28
AU2016366548B2 (en) 2023-12-14
US11859007B2 (en) 2024-01-02
US20210253727A1 (en) 2021-08-19
JP2022104941A (ja) 2022-07-12
EP3387442A1 (en) 2018-10-17
US10822426B2 (en) 2020-11-03
IL259927B2 (en) 2023-05-01
ZA201803874B (en) 2020-11-25
EA201891366A1 (ru) 2018-12-28
WO2017100670A1 (en) 2017-06-15
IL259927A (en) 2018-07-31
CA3007646A1 (en) 2017-06-15
IL259927B1 (en) 2023-01-01

Similar Documents

Publication Publication Date Title
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
NZ738008A (en) Tigit-binding agents and uses thereof
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12018500906A1 (en) Antibodies specifically binding pd-1 and their uses
PH12017502180A1 (en) Tau-binding antibodies
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2019007021A (es) Anticuerpos il-11ra.
EP3635012A4 (en) USE OF ANTI-B7H3 ANTIBODIES TO TREAT CANCER IN THE CENTRAL NERVOUS SYSTEM
MX2017006094A (es) Anticuerpos anti-interleucina-33 y sus usos.
UA120060C2 (uk) Виділене біспецифічне антитіло до cd123 (il3-r-alpha)хcd3 і його застосування
MX2016016881A (es) Anticuerpos que se unen a axl.
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
SG10201909716RA (en) Modified j-chain
PH12017502207A1 (en) Tau-binding antibodies
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2022001085A (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
MX2022012013A (es) Composiciones y metodos para transduccion de tumores.
EP3606962A4 (en) TREATMENT METHODS FOR HIGH CD73 TUMORS
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
EP3383497A4 (en) NEW ANTIBODIES FOR THE TREATMENT OF CANCERS
IL268007A (en) Anti-TNF antibodies, preparations and methods for the treatment of active psoriatic arthritis